SCHEMBL5136272

SCHEMBL5136272

CCCCn1c(CN(CCc2ccc(SC)cc2)Cc2ccc3c(c2)OCO3)cnc1-c1cccc(F)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
F2R P25116 3/20 0.41
HTR2A P28223 3/20 0.39
HTR2C P28335 3/20 0.39
HTR2B P41595 3/20 0.39
CTSL P07711 1/20 0.39
POLB P06746 2/20 0.37
TP53 P04637 2/20 0.37
TSHR P16473 2/20 0.36
USP2 O75604 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSP90AA1 P07900 1/20 0.35
HSP90AB1 P08238 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135932 0.94 C5AR1 (0.46) C5AR1F2RHTR2AHTR2CHTR2B
SCHEMBL5136695 0.92 C5AR1 (0.43) C5AR1F2RHTR2AHTR2CHTR2B
SCHEMBL5137390 0.91 C5AR1 (0.44) C5AR1F2RHTR2AHTR2CHTR2B
SCHEMBL5136312 0.90 HTR2A (0.44) C5AR1F2RHTR2AHTR2CHTR2B
SCHEMBL4768999 0.89 C5AR1 (0.51) C5AR1F2RHTR2AHTR2CHTR2B
SCHEMBL5136963 0.89 C5AR1 (0.47) C5AR1F2RHTR2AHTR2CHTR2B
SCHEMBL5134864 0.87 HTR2A (0.57) HTR2AHTR2CHTR2BTP53SMN1; SMN2
SCHEMBL5135288 0.87 HTR2A (0.51) C5AR1F2RHTR2AHTR2CHTR2B
SCHEMBL5136006 0.86 C5AR1 (0.46) C5AR1F2RHTR2AHTR2CHTR2B
SCHEMBL14415541 0.86 C5AR1 (0.52) C5AR1F2RHTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed